Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 40, Issue 7, 2007, Pages 683-689

  Barkholt, L ^a   Remberger, M ^a   Bodegard H ^a   Ringden O ^a   Bottiger Y ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PSORALEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SOLID TUMOR; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34648844149     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705788     Document Type: Article

References (29)

1. Cantarovich M, Fitchett D, Latter DA. Cyclosporine trough levels, acute rejection, and renal dysfuncuon after heart transplantation. Transplantation 1995; 59: 444-447.
2. Cole E, Keown P, Landsberg D, Halloran P, Shocker A, Rush D et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: A report of the Canadian Neoral Renal Study Group. Transplantation 1998; 65: 505-510.
3. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
4. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68: 1839-1842.
5. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486.
6. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16: 378-382.
7. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin AB, Fortina AB et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005; 18: 116-124.
8. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953-959.
9. Langers P, Cremers SC, den Hartigh J, Veenendaal RA, ten Hove WR, Ringers J et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transpl 2004; 10: 183-189.
10. Billaud EM. C2 versus C0 cyclosporine monitoring: Still not the end. Transplantation 2005; 80: 542; author reply 543-544.
11. Nashan B, Bock A, Bosmans JL, Budde K, Fijter H, Jaques B et al. Use of Neoral C monitoring: A European consensus. Transpl Int 2005; 18: 768-778.
12. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 h: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39 225-235.
13. Ringden O, Remberger M, Runde V, Bornhäuser M, Blau IW, Basara N et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
14. Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andström E et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
15. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersäll P, Pisa P et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
16. Remberger M, Svahn BM, Hentschke P, Löfgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 923-830.
17. Ringden O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221-226.
18. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
19. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004; 78 1014-1020.
20. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
21. Ringden O, Blom B, Collste H, Gahrton G, Groth CG, Grimfors G et al. Bone marrow transplantation for aplastic anemia and acute leukemia at Huddinge Hospital. Scand J Urol Nephrol Suppl 1981; 64: 238-245.
22. Ringden O. Management of graft-versus-host disease. Eur J Haematol 1993; 51: 1-12.
23. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
24. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
25. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
26. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Bums LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
27. Ringden O, Remberger M, Carlens, S, Hägglund H, Mattsson J, Aschan J et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66: 620-625.
28. Hendriks MP, Blijlevens NM, Schattenberg AV, Burger DM, Donelly JP. Cyclosporine short infusion and C(2) monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 521-525.
29. Remberger M, Jaksch M, Uzunel M, Mattsson J. Serum levels of cytokines correlate to donor chimerism and acute graft-vs-host disease after haematopoietic stem cell transplantation. Eur J Haematol 2003; 70: 384-391.